Preferred Label : Caplacizumab;
NCIt synonyms : Caplacizumab-yhdp;
NCIt definition : A humanized, bivalent anti-von Willebrand factor (VWF) nanobody, with potential anti-platelet
and anti-thrombotic activities. Upon administration, caplacizumab specifically binds,
with its two identical monovalent moieties, to the A1 domain of the adhesive glycoprotein
VWF, thereby inhibiting and neutralizing VWF activity. This prevents the interaction
of ultra-large VWF (ULVWF) with the platelet glycoprotein (GP)Ib-IX-V receptor complex,
and prevents ULVWF-mediated platelet adhesion, and aggregation, which reduces thrombus
formation. VWF is a glycoprotein and plays a key role in blood coagulation. Increased
VWF, which is seen in a number of diseases, is associated with an increased risk in
thrombosis; in thrombotic thrombocytopenic purpura (TTP), increased levels of ULVWF
and thus increased and abnormal platelet aggregation are seen due to impaired breakdown
of ULVWF. The nanobody formulation allows for rapid distribution, onset of action
and clearance. The nanobody is based on the smallest functional fragments of the immunoglobulin
heavy-chain variable domains that occur naturally in the Camelidae family.;
UNII : 2R27AB6766;
CAS number : 915810-67-2;
Drug name : Cablivi;
Molecule name : ALX-0681; ALX 0081; ALX-0081; ALX 0681;
Codes from synonyms : 87;
Origin ID : C128625;
UMLS CUI : C3713057;
Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
